Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGN Allergan	$193.02	$190.89	$114.27 ▼ $202.21	$63.50B	1.2	4.01 million shs	12.44 million shs
BAYRY Bayer Aktiengesellschaft	$7.78 -0.4%	$7.12	$4.79 ▼ $8.58	$30.69B	0.86	553,812 shs	189,611 shs
TAK Takeda Pharmaceutical	$15.44 +0.5%	$14.84	$12.80 ▼ $15.66	$48.91B	0.23	1.98 million shs	1.46 million shs
VRTX Vertex Pharmaceuticals	$457.03 +1.1%	$453.08	$377.85 ▼ $519.88	$116.11B	0.41	1.42 million shs	978,282 shs
ZTS Zoetis	$159.09 -0.1%	$160.76	$139.70 ▼ $200.33	$70.87B	0.91	2.57 million shs	2.13 million shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGN Allergan	0.00%	0.00%	0.00%	0.00%	0.00%
BAYRY Bayer Aktiengesellschaft	+3.58%	+1.43%	+10.62%	+33.96%	+12.05%
TAK Takeda Pharmaceutical	-0.52%	+1.89%	+2.47%	+2.67%	+18.44%
VRTX Vertex Pharmaceuticals	+1.56%	+0.42%	+2.07%	-6.48%	-4.05%
ZTS Zoetis	+2.07%	+0.84%	-5.70%	-2.75%	-7.82%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AGN Allergan	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BAYRY Bayer Aktiengesellschaft	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TAK Takeda Pharmaceutical	1.2496 of 5 stars	0.0	3.0	2.5	0.0	2.6	0.0	0.6
VRTX Vertex Pharmaceuticals	4.7176 of 5 stars	3.3	5.0	0.0	3.3	3.4	2.5	1.3
ZTS Zoetis	4.8304 of 5 stars	3.5	5.0	4.2	0.4	3.0	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGN Allergan	0.00	N/A	N/A	N/A
BAYRY Bayer Aktiengesellschaft	3.25	Buy	N/A	N/A
TAK Takeda Pharmaceutical	3.00	Buy	N/A	N/A
VRTX Vertex Pharmaceuticals	2.54	Moderate Buy	$511.62	11.94% Upside
ZTS Zoetis	3.00	Buy	$212.13	33.34% Upside

Current Analyst Ratings Breakdown

Latest AGN, VRTX, ZTS, TAK, and BAYRY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/23/2025	VRTX Vertex Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$550.00
6/20/2025	VRTX Vertex Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$464.00 ➝ $460.00
6/18/2025	ZTS Zoetis	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$165.00 ➝ $160.00
6/17/2025	VRTX Vertex Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Sector Perform ➝ Sector Perform	$423.00 ➝ $420.00
6/11/2025	BAYRY Bayer Aktiengesellschaft	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
6/11/2025	BAYRY Bayer Aktiengesellschaft	Kepler Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy
6/5/2025	BAYRY Bayer Aktiengesellschaft	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
5/23/2025	VRTX Vertex Pharmaceuticals	Erste Group Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/12/2025	ZTS Zoetis	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$205.00 ➝ $210.00
5/7/2025	VRTX Vertex Pharmaceuticals	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Peer Perform
5/7/2025	ZTS Zoetis	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$189.00 ➝ $170.00

(Data available from 7/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGN Allergan	$16.09B	3.95	$36.70 per share	5.26	$177.28 per share	1.09
BAYRY Bayer Aktiengesellschaft	$50.44B	0.61	$3.78 per share	2.06	$8.82 per share	0.88
TAK Takeda Pharmaceutical	$30.09B	1.63	$3.20 per share	4.83	$14.39 per share	1.07
VRTX Vertex Pharmaceuticals	$11.02B	10.65	N/A	N/A	$63.72 per share	7.17
ZTS Zoetis	$9.26B	7.65	$7.07 per share	22.51	$10.57 per share	15.05

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGN Allergan	-$5.27B	$17.64	N/A	10.65	1.63	-15.44%	8.46%	5.31%	N/A
BAYRY Bayer Aktiengesellschaft	-$2.76B	-$0.92	N/A	6.82	N/A	-7.26%	13.94%	4.09%	8/5/2025 (Estimated)
TAK Takeda Pharmaceutical	$712.33M	$0.22	70.19	9.36	N/A	2.36%	10.64%	5.14%	7/30/2025 (Estimated)
VRTX Vertex Pharmaceuticals	-$535.60M	-$3.92	N/A	26.10	N/A	-8.91%	-3.36%	-2.42%	7/30/2025 (Estimated)
ZTS Zoetis	$2.49B	$5.57	28.56	23.57	2.64	27.12%	55.48%	19.14%	8/5/2025 (Estimated)

Latest AGN, VRTX, ZTS, TAK, and BAYRY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/30/2025	Q1 2026	TAK Takeda Pharmaceutical	$0.47	N/A	N/A	N/A	$7.96 billion	N/A
5/13/2025	Q1 2025	BAYRY Bayer Aktiengesellschaft	$0.63	$0.65	+$0.02	$0.35	$13.39 billion	$15.27 billion
5/8/2025	Q4 2025	TAK Takeda Pharmaceutical	$0.24	$0.16	-$0.08	-$0.21	$8.02 billion	$7.34 billion
5/6/2025	Q1 2025	ZTS Zoetis	$1.40	$1.48	+$0.08	$1.41	$2.20 billion	$2.22 billion
5/5/2025	Q1 2025	VRTX Vertex Pharmaceuticals	$4.29	$4.06	-$0.23	$2.49	$2.85 billion	$2.77 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGN Allergan	$2.96	1.53%	N/A	16.78%	N/A
BAYRY Bayer Aktiengesellschaft	$0.02	0.26%	N/A	N/A	N/A
TAK Takeda Pharmaceutical	$0.55	3.56%	N/A	250.00%	N/A
VRTX Vertex Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ZTS Zoetis	$2.00	1.26%	N/A	35.91%	14 Years

Latest AGN, VRTX, ZTS, TAK, and BAYRY Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/22/2025	ZTS Zoetis	quarterly	$0.50	1.2%	7/18/2025	7/18/2025	9/3/2025
4/22/2025	BAYRY Bayer Aktiengesellschaft		$0.0224	0.38%	4/29/2025	4/30/2025	5/12/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGN Allergan	0.31	1.01	0.84
BAYRY Bayer Aktiengesellschaft	1.07	1.25	0.79
TAK Takeda Pharmaceutical	0.57	1.01	0.52
VRTX Vertex Pharmaceuticals	0.01	2.65	2.29
ZTS Zoetis	1.12	1.74	1.04

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGN Allergan	83.91%
BAYRY Bayer Aktiengesellschaft	N/A
TAK Takeda Pharmaceutical	9.17%
VRTX Vertex Pharmaceuticals	90.96%
ZTS Zoetis	92.80%

Insider Ownership

Company	Insider Ownership
AGN Allergan	0.08%
BAYRY Bayer Aktiengesellschaft	N/A
TAK Takeda Pharmaceutical	0.04%
VRTX Vertex Pharmaceuticals	0.20%
ZTS Zoetis	0.18%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGN Allergan	17,400	329.00 million	N/A	Optionable
BAYRY Bayer Aktiengesellschaft	92,815	3.93 billion	N/A	Not Optionable
TAK Takeda Pharmaceutical	49,281	3.18 billion	3.18 billion	Optionable
VRTX Vertex Pharmaceuticals	6,100	256.80 million	256.28 million	Optionable
ZTS Zoetis	13,800	445.21 million	444.41 million	Optionable

AGN, VRTX, ZTS, TAK, and BAYRY Headlines

Recent News About These Companies

ZTS - Zoetis Inc Class A Executives - Morningstar

July 2 at 3:52 PM | morningstar.comM

2 of Wall Street’s Favorite Stocks to Research Further and 1 to Question

July 2 at 10:50 AM | finance.yahoo.com

2,305 Shares in Zoetis Inc. (NYSE:ZTS) Purchased by Horizon Financial Services LLC

July 2 at 9:31 AM | marketbeat.com

Here's Why Zoetis (ZTS) is a Strong Growth Stock

July 1 at 10:45 AM | zacks.com

Zoetis to Host Webcast and Conference Call on Second Quarter 2025 Financial Results

July 1 at 9:02 AM | businesswire.com

Zoetis Inc. (NYSE:ZTS) Shares Purchased by Summit Trail Advisors LLC

July 1 at 8:47 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Shares Acquired by Sumitomo Mitsui DS Asset Management Company Ltd

July 1 at 8:38 AM | marketbeat.com

Vontobel Holding Ltd. Has $279.75 Million Stake in Zoetis Inc. (NYSE:ZTS)

July 1 at 7:44 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Shares Sold by Kampmann Melissa S.

July 1 at 7:24 AM | marketbeat.com

Hixon Zuercher LLC Buys New Shares in Zoetis Inc. (NYSE:ZTS)

July 1 at 7:05 AM | marketbeat.com

New York State Teachers Retirement System Has $61.81 Million Holdings in Zoetis Inc. (NYSE:ZTS)

July 1 at 5:18 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Shares Purchased by Amalgamated Bank

July 1 at 5:08 AM | marketbeat.com

Mirae Asset Global Investments Co. Ltd. Has $11.18 Million Stake in Zoetis Inc. (NYSE:ZTS)

July 1 at 4:34 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Shares Acquired by KBC Group NV

June 30 at 5:37 AM | marketbeat.com

Sumitomo Mitsui Trust Group Inc. Sells 64,413 Shares of Zoetis Inc. (NYSE:ZTS)

June 29 at 5:48 AM | marketbeat.com

Vista Investment Partners II LLC Buys 1,878 Shares of Zoetis Inc. (NYSE:ZTS)

June 28, 2025 | marketbeat.com

Achmea Investment Management B.V. Increases Stock Position in Zoetis Inc. (NYSE:ZTS)

June 28, 2025 | marketbeat.com

Sequoia Financial Advisors LLC Sells 170,846 Shares of Zoetis Inc. (NYSE:ZTS)

June 28, 2025 | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Shares Sold by Bessemer Group Inc.

June 28, 2025 | marketbeat.com

Should You Invest in Zoetis (ZTS) Based on Bullish Wall Street Views?

June 27, 2025 | zacks.com

Quilter Plc Has $61.88 Million Stake in Zoetis Inc. (NYSE:ZTS)

June 27, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Applied Digital: Now the High-Stakes Race to Build Begins
By Jeffrey Neal Johnson | June 17, 2025
View Applied Digital: Now the High-Stakes Race to Build Begins
Archer's Midnight Air Taxi Soars, But Stock Doesn’t Budge
By Jeffrey Neal Johnson | June 4, 2025
View Archer's Midnight Air Taxi Soars, But Stock Doesn’t Budge
Lululemon, UNH, Enphase: Bad News, Good Opportunity?
By Thomas Hughes | June 17, 2025
View Lululemon, UNH, Enphase: Bad News, Good Opportunity?
Tankers, Takedowns & Air Taxis: Insiders Are Buying These 3 Names
By Leo Miller | June 10, 2025
View Tankers, Takedowns & Air Taxis: Insiders Are Buying These 3 Names
Rivian vs. Lucid: Who’s Best Positioned to Steal Tesla’s Thunder?
By Nathan Reiff | June 20, 2025
View Rivian vs. Lucid: Who’s Best Positioned to Steal Tesla’s Thunder?

AGN, VRTX, ZTS, TAK, and BAYRY Company Descriptions

Allergan NYSE:AGN

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products. The company also offers breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. In addition, it develops medical and cosmetic treatments; therapies for non-alcoholic steatohepatitis and other liver diseases; inhibitor for the treatment of psoriasis and other autoimmune disorders; atopic dermatitis drug candidate; peri-ocular rings for extended drug delivery and reducing elevated intraocular pressure in glaucoma patients; and treatments for neurodegenerative disorders, including Alzheimer's disease. Further, the company develops RST-001, a novel gene therapy for the treatment of retinitis pigmentosa; small molecule therapeutics for inflammatory and fibrotic diseases; topical medicines for fat reduction; and delivery system and botulinum toxin-based prescription products. It has collaboration, option, and license agreement with Lyndra, Inc.; and strategic alliance and option agreement with Editas Medicine, Inc. Allergan plc also has licensing agreements with Assembly Biosciences, Inc.; MedImmune; and Heptares Therapeutics, Ltd. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.

Bayer Aktiengesellschaft OTCMKTS:BAYRY

$7.78 -0.03 (-0.38%)

As of 03:59 PM Eastern

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines for self-medication and self-care; and solutions for nutritional supplements, allergy, cough and cold, dermatology, pain and cardiovascular risk prevention, and digestive health. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration with Acuitas Therapeutics, Inc. to strengthen gene editing programs; Peking University in the area of basic pharmaceutical research; the Swiss Tropical and Public Health Institute in the development of the compound emodepside for the treatment of infection with soil-transmitted helminths; bit.bio Ltd. for the discovery and manufacture of regulatory T cells for use in creating therapeutics; Hologic, Inc. in the field of contrastenhanced-mammography solutions to improve diagnostic imaging for the detection of breast cancer; and Twist Bioscience Corporation centering around the research and development of antibody-based pharmaceuticals, as well as with CrossBay Medical Inc. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company has collaboration with Thermo Fisher Scientific. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.

Takeda Pharmaceutical NYSE:TAK

$15.44 +0.07 (+0.46%)

Closing price 03:59 PM Eastern

Extended Trading

$15.46 +0.02 (+0.13%)

As of 07:58 PM Eastern

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

Vertex Pharmaceuticals NASDAQ:VRTX

$457.03 +4.87 (+1.08%)

Closing price 04:00 PM Eastern

Extended Trading

$457.50 +0.47 (+0.10%)

As of 07:51 PM Eastern

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Zoetis NYSE:ZTS

$159.09 -0.10 (-0.06%)

Closing price 03:59 PM Eastern

Extended Trading

$159.10 +0.01 (+0.01%)

As of 06:53 PM Eastern

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare MarketRank™

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AGN, VRTX, ZTS, TAK, and BAYRY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AGN, VRTX, ZTS, TAK, and BAYRY Earnings

Compare Dividends

Latest AGN, VRTX, ZTS, TAK, and BAYRY Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AGN, VRTX, ZTS, TAK, and BAYRY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

AGN, VRTX, ZTS, TAK, and BAYRY Company Descriptions

Allergan NYSE:AGN

Bayer Aktiengesellschaft OTCMKTS:BAYRY

Takeda Pharmaceutical NYSE:TAK

Vertex Pharmaceuticals NASDAQ:VRTX

Zoetis NYSE:ZTS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools